Overactive Bladder (OAB) Therapeutics Market to Reach $4.86 Billion by 2035

Overactive Bladder (OAB) therapeutics market was valued at $3.53 billion in 2025 and is projected to reach $4.86 billion by 2035, expanding at a CAGR of 3.4% over the forecast period from 2026 to 2035. The growing prevalence of Overactive Bladder (OAB) globally is a principal driver of demand for therapeutics, directly expanding the addressable patient population for both anticholinergic agents and beta-3 adrenoreceptor agonists. A rigorous meta-analysis incorporating more than 610,000 participants estimates the global prevalence of OAB at around 20%, indicating that a substantial share of adults experience symptoms requiring clinical management. Over the past two decades, prevalence has climbed from roughly 18.1% to 23.9%, reflecting demographic shifts and increasing risk factor burdens such as aging and obesity. This upward trend elevates clinical urgency for effective pharmacological treatments and stimulates innovation, prescribing, and healthcare engagement across hospitals and clinics. As prevalence continues to rise globally, OAB therapeutics are gaining priority in treatment protocols and pharmaceutical development, underlining the condition’s growing epidemiological and commercial significance.

Browse the full report description of “Overactive Bladder (OAB) Therapeutics Market Size, Share & Trends Analysis Report by Type (Anticholinergic Agents, and Beta-3 Adrenoreceptor Agonists), and by Application (Hospitals, Clinics, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/overactive-bladder-oab-therapeutics-market

Epidemiological evidence shows that approximately 20% of adults globally live with OAB, with prevalence increasing over the past 20 years; women have higher rates (about 21.9%) than men (around 16.1%), and older adults and those with elevated body mass index exhibit significantly higher prevalence.

Recent Regulatory Approvals, Clinical Developments, and Strategic Moves in the OAB Therapeutics Market

• In September 2025, MSN Labs received clearance from India’s CDSCO Subject Expert Committee to initiate a Phase III clinical trial of vibegron 75 mg for the treatment of overactive bladder. The approval followed submission of a revised clinical protocol that incorporated feedback from earlier regulatory reviews.

• In December 2024, Sumitomo Pharma America announced that the US Food and Drug Administration approved GEMTESA (vibegron) 75 mg, a once-daily beta-3 adrenergic receptor agonist, for men with overactive bladder symptoms who are concurrently undergoing treatment for benign prostatic hyperplasia.

• In November 2024, Boston Scientific completed the acquisition of Axonics, a medical technology company focused on therapies for urinary and bowel dysfunction. The transaction strengthened Boston Scientific’s urology portfolio by adding sacral neuromodulation capabilities and expanding its range of treatment options globally.

• In July 2024, the European Commission granted approval for OBGEMSA (vibegron), developed by Pierre Fabre Laboratories, for the treatment of overactive bladder in adults. The authorization followed Pierre Fabre’s exclusive licensing agreement with Urovant Sciences in 2022 and applies across all EU member states, as well as Iceland, Liechtenstein, and Norway.

• In April 2024, Zydus Lifesciences launched Mirabegron 25 mg extended-release tablets in the US market after receiving final approval from the USFDA. The introduction of this generic therapy expanded treatment availability within the overactive bladder segment.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Type
  • Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – AbbVie Inc., Astellas Pharma Inc., Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Overactive Bladder (OAB) Therapeutics Market Report Segment

By Type

• Anticholinergic Agents
• Beta-3 Adrenoreceptor Agonists

By Application

• Hospitals
• Clinics
• Others

Global Overactive Bladder (OAB) Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/overactive-bladder-oab-therapeutics-market